Cognition Therapeutics (CGTX)
US Market

Cognition Therapeutics Stock Analysis & Ratings

CGTX Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$1.50 - $13.80
Previous Close$2.25
Average Volume (3M)57.78K
Market CapN/A
Enterprise ValueN/A
P/E Ratio-2.6
Next EarningsMay 11, 2022
Next Dividend Ex-DateN/A
Dividend YieldN/A
Smart Score4



P/E Ratio Range

The price to earnings ratio. This is used by investors to assess a stock’s market price relative to its earnings.


Risk Analysis

Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products

Product Monthly Users

Sorry, No Data Available
There is no website visitor data available for this stock.



What was Cognition Therapeutics’s price range in the past 12 months?
Cognition Therapeutics lowest stock price was $1.50 and its highest was $13.80 in the past 12 months.
    What is Cognition Therapeutics’s market cap?
    Currently, no data Available
    What is Cognition Therapeutics’s price target?
    The average price target for Cognition Therapeutics is $12.50. This is based on 2 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
    The highest analyst price target is $15.00 ,the lowest forecast is $10.00. The average price target represents 455.56% Increase from the current price of $2.25.
      What do analysts say about Cognition Therapeutics?
      Cognition Therapeutics’s analyst rating consensus is a ‘Moderate Buy. This is based on the ratings of 2 Wall Streets Analysts.
        When is Cognition Therapeutics’s upcoming earnings report date?
        Cognition Therapeutics’s upcoming earnings report date is May 11, 2022 which is 54 days ago.
          How were Cognition Therapeutics’s earnings last quarter?
          Cognition Therapeutics released its earnings results on Mar 30, 2022. The company reported -$0.415 earnings per share for the quarter, missing the consensus estimate of -$0.26 by -$0.155.
            Is Cognition Therapeutics overvalued?
            According to Wall Street analysts Cognition Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
              Does Cognition Therapeutics pay dividends?
              Cognition Therapeutics does not currently pay dividends.
              What is Cognition Therapeutics’s EPS estimate?
              Cognition Therapeutics’s EPS estimate is -$0.29.
                How many shares outstanding does Cognition Therapeutics have?
                Cognition Therapeutics has 22,597,906 shares outstanding.
                  What happened to Cognition Therapeutics’s price movement after its last earnings report?
                  Cognition Therapeutics reported an EPS of -$0.415 in its last earnings report, missing expectations of -$0.26. Following the earnings report the stock price went down -7.407%.
                    Which hedge fund is a major shareholder of Cognition Therapeutics?
                    Currently, no hedge funds are holding shares in CGTX


                    Cognition Therapeutics Stock Analysis

                    The Cognition Therapeutics stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                    Learn more about TipRanks Smart Score

                    Company Description

                    Cognition Therapeutics

                    Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of innovative, small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina.

                    Popular Stocks

                    What's Included in PREMIUM?
                    Make informed decisions based on Top Analysts' activity
                    Know what industry insiders are buying
                    Get actionable alerts from top Wall Street Analysts
                    Find out before anyone else which stock is going to shoot up
                    Get powerful stock screeners & detailed portfolio analysis